Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
46
IOSP Quote, Financials, Valuation and Earnings
Last price:
$84.95
Seasonality move
:
-0.48%
Day range:
$84.26 - $85.81
52-week range:
$80.32 - $133.53
Dividend yield:
1.93%
P/E ratio:
79.75x
P/S ratio:
1.19x
P/B ratio:
1.67x
Volume:
169.1K
Avg. volume:
226.6K
1-year change:
-35.1%
Market cap:
$2.1B
Revenue:
$1.8B
EPS (TTM):
$1.06
Analysts' Opinion
-
Consensus RatingInnospec has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $115.00, Innospec has an estimated upside of 36.05% from its current price of $84.53.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $115.00 representing 100% downside risk from its current price of $84.53.
Fair Value
-
According to the consensus of 1 analyst, Innospec has 36.05% upside to fair value with a price target of $115.00 per share.
IOSP vs. S&P 500
-
Over the past 5 trading days, Innospec has underperformed the S&P 500 by -5.33% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Innospec does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Innospec revenues have been falling on a year-over-year basis for 7 quarters in a row. In the most recent quarter Innospec reported revenues of $440.8M.
Earnings Growth
-
Innospec earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Innospec reported earnings per share of $1.31.
Enterprise value:
1.8B
EV / Invested capital:
--
Price / LTM sales:
1.19x
EV / EBIT:
10.61x
EV / Revenue:
1.02x
PEG ratio (5yr expected):
1.39x
EV / Free cash flow:
26.43x
Price / Operating cash flow:
30.90x
Enterprise value / EBITDA:
8.44x
Gross Profit (TTM):
$512.3M
Return On Assets:
1.55%
Net Income Margin (TTM):
1.51%
Return On Equity:
2.21%
Return On Invested Capital:
2.21%
Operating Margin:
9.76%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $2B | $1.9B | $1.8B | $500.2M | $440.8M | |
| Gross Profit | $595.2M | $599M | $512.3M | $155.7M | $125.1M | |
| Operating Income | $185.7M | $171.8M | $171.2M | $52.9M | $43M | |
| EBITDA | $221M | $212.2M | $215.2M | $63.3M | $53.9M | |
| Diluted EPS | $5.19 | $5.89 | $1.06 | $1.65 | $1.31 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $607.6M | $778.6M | $875M | $912.9M | $977.1M | |
| Total Assets | $1.4B | $1.6B | $1.6B | $1.7B | $1.8B | |
| Current Liabilities | $274.3M | $352.3M | $381.6M | $364.9M | $357.6M | |
| Total Liabilities | $467M | $554.9M | $543.5M | $546.6M | $508.9M | |
| Total Equity | $959.1M | $1.1B | $1.1B | $1.2B | $1.3B | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $132.5M | $266.1M | $132.2M | $80.6M | $28.3M | |
| Cash From Investing | -$55.7M | -$104.1M | -$63.2M | -$14.3M | -$15.5M | |
| Cash From Financing | -$34.2M | -$38.9M | -$39.6M | $500K | -$3.8M | |
| Free Cash Flow | $76.6M | $196.5M | $68.7M | $66.2M | $12.7M | |
IOSP
Sector
Market Cap
$2.1B
$19.1M
Price % of 52-Week High
63.3%
70.42%
Dividend Yield
1.93%
0%
Shareholder Yield
1.78%
0.73%
1-Year Price Total Return
-35.1%
-6.33%
Beta (5-Year)
1.047
0.736
Dividend yield:
1.93%
Annualized payout:
$1.55
Payout ratio:
143.7%
Growth streak:
11 years
Technicals
8-day SMA
Sell
Level
$87.40
200-day SMA
Sell
Level
$102.12
Bollinger Bands (100)
Sell
Level
84.79 - 96.71
Chaikin Money Flow
Buy
Level
222.7K
20-day SMA
Sell
Level
$85.77
Relative Strength Index (RSI14)
Sell
Level
42.52
ADX Line
Sell
Level
14.41
Williams %R
Buy
Level
-86.3173
50-day SMA
Sell
Level
$87.05
MACD (12, 26)
Buy
Level
23.61
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Neutral
Level
256K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.8186)
Buy
CA Score
(Annual)
Level (1.2805)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-0.0595)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Innospec Inc manufactures and sells a variety of chemicals and fuel additives. The firm organizes itself into three segments based on product type. The Fuel Specialties segment, which generates the majority of revenue, sells products used to improve fuel efficiency, boost engine performance, and reduce emissions for automobiles, boats, and airplanes. It also sells products used by oil field service providers in the extraction of oil and gas. The Performance Chemicals segment sells products to the personal-care industry. The Oilfield Services segment develops and markets products to prevent loss of mud.
Stock Forecast FAQ
In the current month, IOSP has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The IOSP average analyst price target in the past 3 months is $115.00.
-
Where Will Innospec Stock Be In 1 Year?
According to analysts, the consensus estimate is that Innospec share price will rise to $115.00 per share over the next 12 months.
-
What Do Analysts Say About Innospec?
Analysts are divided on their view about Innospec share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Innospec is a Sell and believe this share price will drop from its current level to $115.00.
-
What Is Innospec's Price Target?
The price target for Innospec over the next 1-year time period is forecast to be $115.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is IOSP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Innospec is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of IOSP?
You can purchase shares of Innospec via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Innospec shares.
-
What Is The Innospec Share Price Today?
Innospec was last trading at $84.95 per share. This represents the most recent stock quote for Innospec. Yesterday, Innospec closed at $84.53 per share.
-
How To Buy Innospec Stock Online?
In order to purchase Innospec stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
